Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asaf Maoz

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Expert Opinion on Emerging Drugs|November 23, 2019
Emerging serine-threonine kinase inhibitors for treating ovarian cancerAsaf Maoz, Marcia A Ciccone, Shinya Matsuzaki, et al.
American Journal of Hematology|December 22, 2018
Bortezomib ocular toxicities: Outcomes with ketotifenMichael Dennis, Asaf Maoz, David Hughes, et al.
Expert Opinion on Investigational Drugs|April 22, 2016
Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literatureMarcia A Ciccone, Asaf Maoz, Jennifer K Casabar, et al.
Gynecologic Oncology|November 16, 2020
Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancerKoji Matsuo, Shinya Matsuzaki, David J Nusbaum, et al.
Cancers|June 4, 2020
Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord-Stromal Tumors: A Contemporary ReviewAsaf Maoz, Koji Matsuo, Marcia A Ciccone, et al.
JCO Precision Oncology|April 28, 2025
Intratumoral Heterogeneity of Mismatch Repair Status and Outcome of Treatment With Dostarlimab in a Patient With Locally Advanced Rectal AdenocarcinomaAsaf Maoz, Ronald Bleday, Jeffrey Goldsmith, et al.
JCO Precision Oncology|October 11, 2025
Causes of Death Among Individuals With Lynch Syndrome in the Immunotherapy EraAsaf Maoz, Leah Biller, Marios Giannakis, et al.
Biorxiv : the Preprint Server for Biology|March 22, 2023
Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destructionKyle Vaccaro, Juliet Allen, Troy W Whitfield, et al.
The Journal of Clinical Investigation|March 14, 2024
Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destructionKyle Vaccaro, Juliet Allen, Troy W Whitfield, et al.
Journal for Immunotherapy of Cancer|September 28, 2021
Elevated T cell repertoire diversity is associated with progression of lung squamous cell premalignant lesionsAsaf Maoz, Carter Merenstein, Yusuke Koga, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Expert Opinion on Emerging Drugs|November 23, 2019
Emerging serine-threonine kinase inhibitors for treating ovarian cancerAsaf Maoz, Marcia A Ciccone, Shinya Matsuzaki, et al.
American Journal of Hematology|December 22, 2018
Bortezomib ocular toxicities: Outcomes with ketotifenMichael Dennis, Asaf Maoz, David Hughes, et al.
Expert Opinion on Investigational Drugs|April 22, 2016
Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literatureMarcia A Ciccone, Asaf Maoz, Jennifer K Casabar, et al.
Gynecologic Oncology|November 16, 2020
Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancerKoji Matsuo, Shinya Matsuzaki, David J Nusbaum, et al.
Cancers|June 4, 2020
Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord-Stromal Tumors: A Contemporary ReviewAsaf Maoz, Koji Matsuo, Marcia A Ciccone, et al.
JCO Precision Oncology|April 28, 2025
Intratumoral Heterogeneity of Mismatch Repair Status and Outcome of Treatment With Dostarlimab in a Patient With Locally Advanced Rectal AdenocarcinomaAsaf Maoz, Ronald Bleday, Jeffrey Goldsmith, et al.
JCO Precision Oncology|October 11, 2025
Causes of Death Among Individuals With Lynch Syndrome in the Immunotherapy EraAsaf Maoz, Leah Biller, Marios Giannakis, et al.
Biorxiv : the Preprint Server for Biology|March 22, 2023
Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destructionKyle Vaccaro, Juliet Allen, Troy W Whitfield, et al.
The Journal of Clinical Investigation|March 14, 2024
Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destructionKyle Vaccaro, Juliet Allen, Troy W Whitfield, et al.
Journal for Immunotherapy of Cancer|September 28, 2021
Elevated T cell repertoire diversity is associated with progression of lung squamous cell premalignant lesionsAsaf Maoz, Carter Merenstein, Yusuke Koga, et al.
Pageof 3